Pilot and Feasibility Grants

• The use of BBDC data or biological materials is not exempt from review by an Institutional Review Board (IRB). If the Pilot Study will be conducted at a non-BBDC institution, the investigator must provide the IRB approval letter to the Steering Committee before the study begins.
• Studies that will collect new data from participants must obtain a separate informed consent from all pilot study participants. This consent should clearly identify the pilot study as one being performed in addition to the main study and inform subjects that their participation in the pilot study is not required for them to continue in BBDC studies. The IRB approval letter and the informed consent document must be provided to the Steering Committee before study enrollment or data transfer.
• A single IRB model must be used if the study involves multiple BBDC sites.

• A BBDC investigator or other approved collaborating investigator is expected to be a co-investigator or principal investigator on a pilot study in the role of BBDC sponsor. The sponsor is responsible for presenting the study to the Steering Committee, monitoring the study to assure continuing compatibility with BBDC guidelines, and serving as a liaison to the BBDC.
• Pilot studies from industry partners will be subject to additional agreements with more specific criteria regarding data use and financial remuneration to the OI Foundation for access to the data.
• In addition, manuscripts and abstracts are generally expected to include a BBDC sponsor, except under circumstances that should be stated and justified as part of the original proposal.

All BBDC sites designated for inclusion in the study must have agreement from the respective Principal Investigator.

• The data collected by the pilot study and any accompanying documentation are first to be provided to the BBDC Administrative Core for integration into the main database. This must occur before the integrated file containing data from the main study will be sent to the pilot study investigators. The pilot study Lead will be given the first and exclusive opportunity to analyze, present and publish data collected under the auspices of the pilot study. After a reasonable time (in general, 12 months after data collection and cleaning are complete unless the Steering committee deems that the complexity of the analysis warrants extending this timeframe), the pilot study data will be made available for additional uses by other investigators. Collaboration with the pilot study investigators who collected the data is encouraged. It is the responsibility of the pilot study Lead to state in writing to the Steering Committee any special circumstances that would militate against these guidelines for data sharing. In the spirit of encouraging collaboration, reasonable and justified requests for limiting Steering Committee access to the data will be entertained.
• A manuscript proposal must be reviewed and approved by BBDC before data from the main study will be provided to pilot study investigators.

All pilot studies have 6 months from approval to become active (with or without funding), after which they will be withdrawn and must be resubmitted for re-approval. This time frame includes establishment of the sIRB as needed.

All the publications from a pilot study must be reviewed and approved by the BBDC Publications Subcommittee (P&P), Steering Committee, and reviewed by NIAMS prior to submission, in accordance with BBDC publications policy. Publications must reference the BBDC and BBDC NIH funding resources as per consortium publication guidelines (see BBDC publication policy for details).